Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,893 active trials21 approved drugs383 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07310446 | Collection of Samples From the United States Population for Optimization and Evaluation of Colorectal Cancer (CRC) Plasma Circulating Free-DNA (cfDNA) Marker Panel Performance(PROVE) | recruiting | — | 6,500 | Universal DiagnosticsINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY |
| 1 |
| Dec 29, 2025 |
| clinicaltrials |
| NCT07279077 | Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II Trial(MODIFI-L) | recruiting | Phase 2 | 38 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06640283 | Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes(ANA) | recruiting | Phase 2 | 150 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06666192 | The Ohio State University (OSU) SCREEN Community Program | recruiting | N/A | 2,067 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06722183 | Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities(FUTURE) | recruiting | Phase 2 | 33 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06791512 | mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC(BASKETⅢ) | recruiting | Phase 3 | 166 | Jun HuangOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06920680 | ColoReg: A Register for Gastrointestinal Endoscopy Reports and Examination Videos | recruiting | — | 1,834 | Wuerzburg University HospitalOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06934538 | First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 90 | Brenus PharmaINDUSTRY | 3 | Dec 22, 2025 | clinicaltrials |
| NCT07262957 | Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)(PANENCA) | recruiting | Phase 4 | 400 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07296237 | Beyond Survival: Addressing Gynecological and Sexual Health in Women After Radiotherapy for Anal Cancer(DACG VI) | recruiting | — | 80 | Aarhus University HospitalOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT05663203 | A Web-Based Dyadic Intervention for Colorectal Cancer(CRCweb) | recruiting | N/A | 56 | Emory UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07153458 | Identification of New Non-invasive, Predictive, and Diagnostic Biomarkers for Colorectal Cancer | recruiting | — | 60 | Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07192068 | Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.(AcSé HER2) | recruiting | Phase 2 | 105 | UNICANCEROTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05943444 | Comparison of Postoperative Anal Function Between Parks and Bacon Techniques in Low Rectal Cancer | recruiting | N/A | 256 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06686576 | A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer | recruiting | Phase 3 | 363 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05472948 | Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma | recruiting | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05856981 | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | recruiting | Phase 1 | 130 | Sairopa B.V.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT05959356 | Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer(CEIL) | recruiting | Phase 2 | 198 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06714357 | ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer(VICTORIA) | recruiting | Phase 2 | 130 | National Cancer Institute, NaplesOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07213570 | STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer | recruiting | Phase 2 | 60 | National Cancer Institute, NaplesOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT04722341 | Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators | recruiting | N/A | 175 | Cedars-Sinai Medical CenterOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05391126 | GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care | recruiting | N/A | 178 | Reema A. PatelOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07283575 | Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET) | recruiting | — | 497 | Fudan UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07284992 | SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC | recruiting | Phase 2 | 208 | Shandong Provincial HospitalOTHER_GOV | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07285356 | Study to Evaluate the Use of Surgical Gloves for the Prevention of Oxaliplatin-Induced Peripheral Neuropathy(GLOX-PEN) | recruiting | N/A | 84 | AC Camargo Cancer CenterOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05008809 | Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) | recruiting | Phase 3 | 507 | Dominik Paul ModestOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT06856837 | - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases | recruiting | Phase 2 | 140 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Dec 12, 2025 | clinicaltrials |
| NCT05639413 | A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer(COBRAF) | recruiting | N/A | 400 | UNICANCEROTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05993923 | Impact of a Multidisciplinary Approach in the Perioperative Geriatrics Unit on Functional Status of Patients Aged 70 and Over Operated on for Colorectal Cancer(DIGER) | recruiting | N/A | 90 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT06245356 | Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer(TRIFLUOX-DP) | recruiting | Phase 2 | 73 | UNICANCEROTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT06380101 | Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)(NEAAR-LARC) | recruiting | N/A | 30 | University of South FloridaOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT07221058 | Adaptive Radiation Boost for Rectal Cancer(ARBOR) | recruiting | Phase 1 | 37 | Fox Chase Cancer CenterOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT07272772 | Colon Cancer Diagnosis With FAPI-PET Imaging | recruiting | Phase 2 / Phase 3 | 100 | Turku University HospitalOTHER_GOV | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06733038 | FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.(AtezoTRIBE2) | recruiting | Phase 3 | 238 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07269249 | Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer(RW-NEDOS) | recruiting | — | 50 | National Cancer Institute, NaplesOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06731894 | Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors | recruiting | Phase 2 | 120 | City of Hope Medical CenterOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06236633 | Safety & Efficacy of Ischemic Preconditioning by Embolization of the Inferior Mesenteric Artery in Surgery for Tumors of Lower and Middle Rectum(AMIREMBOL_2) | recruiting | N/A | 30 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06522256 | Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial(HPVsign) | recruiting | N/A | 100 | ANRS, Emerging Infectious DiseasesOTHER_GOV | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07262840 | Health Behavior Change in High-Risk Colorectal Cancer Individuals | recruiting | N/A | 80 | China Medical University, ChinaOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07263178 | A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer. | recruiting | — | 1,000 | Boryung Pharmaceutical Co., LtdINDUSTRY | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07264556 | Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery | recruiting | N/A | 90 | Fudan UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05642819 | REVOLUTION Surgery (REVOLUTION Surgery) | recruiting | — | 200 | University of EdinburghOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05786716 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07230509 | Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate(NBCA) | recruiting | Phase 2 | 90 | Minia UniversityOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07257653 | The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer(concept) | recruiting | Phase 2 | 70 | Zhejiang UniversityOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259590 | A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation | recruiting | Phase 1 / Phase 2 | 126 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06154538 | Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer | recruiting | Phase 2 | 170 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 28, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 30, 2025source: clinicaltrials